Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Diffuse large B-cell lymphoma variants: an update.

Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ.

Pathology. 2019 Nov 14. pii: S0031-3025(19)30399-X. doi: 10.1016/j.pathol.2019.08.013. [Epub ahead of print] Review.

PMID:
31735345
2.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2019 Nov 3. doi: 10.1002/ajh.25671. [Epub ahead of print]

PMID:
31682008
3.

Epstein - Barr virus infection in de novo diffuse large B-cell lymphoma in Jordan and Turkey.

Aladily TN, Mansour AT, Mahgoob R, Khoury JD, Oltulu P, Medeiros LJ.

Ann Diagn Pathol. 2019 Sep 3;43:151406. doi: 10.1016/j.anndiagpath.2019.151406. [Epub ahead of print] No abstract available.

PMID:
31499264
4.

Chronic lymphocytic leukemia with plasmacytic differentiation.

Lyapichev KA, Kurt H, Sukswai N, Konoplev S, Bueso-Ramos CE, Khoury JD, Huh YO.

Ann Hematol. 2019 Oct;98(10):2437-2438. doi: 10.1007/s00277-019-03784-x. Epub 2019 Aug 26. No abstract available.

PMID:
31451834
5.

Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Zuo Z, Li S, Xu J, You MJ, Khoury JD, Yin CC.

Curr Hematol Malig Rep. 2019 Oct;14(5):376-385. doi: 10.1007/s11899-019-00534-8. Review.

PMID:
31388824
6.

PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.

Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, Yin CC, You MJ, Khoury JD, Iyer SP, Miranda RN, Xu J.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0336-3. [Epub ahead of print]

PMID:
31383967
7.

A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.

Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0337-2. [Epub ahead of print]

PMID:
31383966
8.

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function.

Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Ju Lee H, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC.

Leuk Lymphoma. 2019 Aug 2:1-5. doi: 10.1080/10428194.2019.1644333. [Epub ahead of print] No abstract available.

PMID:
31373240
9.

Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications.

Yap K, Cohen EN, Reuben JM, Khoury JD.

Curr Hematol Malig Rep. 2019 Oct;14(5):353-357. doi: 10.1007/s11899-019-00531-x. Review.

PMID:
31364034
10.

Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.

El Achi H, Khoury JD, Loghavi S.

Curr Hematol Malig Rep. 2019 Oct;14(5):358-367. doi: 10.1007/s11899-019-00532-w. Review.

PMID:
31346903
11.

Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.

Sukswai N, Khoury JD.

Curr Hematol Malig Rep. 2019 Oct;14(5):368-375. doi: 10.1007/s11899-019-00533-9. Review.

PMID:
31338668
12.

Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine.

Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, Branton PA, Crothers JW, Cushman-Vokoun AM, Hicks DG, Khoury JD, Laser J, Marshall CB, Misialek MJ, Natale KE, Nowak JA, Olson D, Pfeifer JD, Schade A, Vance GH, Walk EE, Yohe SL.

Arch Pathol Lab Med. 2019 Nov;143(11):1346-1363. doi: 10.5858/arpa.2019-0009-SA. Epub 2019 Jul 22.

PMID:
31329478
13.

Hydroa Vacciniforme-Like Lymphoproliferative Disorder With Progression to EBV+ Cytotoxic Peripheral T-Cell Lymphoma.

Lyapichev KA, Sukswai N, Wang XI, Khoury JD, Medeiros LJ.

Am J Dermatopathol. 2019 Jul 12. doi: 10.1097/DAD.0000000000001494. [Epub ahead of print] No abstract available.

PMID:
31313696
14.

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.

Ning MS, Pinnix CC, Chapman BV, Gunther JR, Milgrom SA, Khoury JD, Jain P, Chen WY, Oriabure ON, Badillo MR, Wang LM, Dabaja BS.

Blood Adv. 2019 Jul 9;3(13):2035-2039. doi: 10.1182/bloodadvances.2019030858.

15.

Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD.

Am J Surg Pathol. 2019 Oct;43(10):1429-1437. doi: 10.1097/PAS.0000000000001316.

PMID:
31261288
16.

Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies.

Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros L.

Data Brief. 2019 May 23;24:104025. doi: 10.1016/j.dib.2019.104025. eCollection 2019 Jun.

17.

TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.

Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S.

Ann Diagn Pathol. 2019 Aug;41:38-42. doi: 10.1016/j.anndiagpath.2019.05.004. Epub 2019 May 16.

PMID:
31132650
18.

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.

Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD.

Br J Haematol. 2019 Aug;186(4):538-548. doi: 10.1111/bjh.15960. Epub 2019 May 22.

PMID:
31115909
19.

Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations.

Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ.

Cancer Genet. 2019 Apr;233-234:21-31. doi: 10.1016/j.cancergen.2019.03.002. Epub 2019 Mar 11.

PMID:
31109591
20.

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD.

Cancers (Basel). 2019 May 19;11(5). pii: E695. doi: 10.3390/cancers11050695.

21.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
22.

Patient with mixed-phenotype acute leukemia with CBFB rearrangement.

Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N.

Leuk Lymphoma. 2019 Nov;60(11):2829-2831. doi: 10.1080/10428194.2019.1605069. Epub 2019 Apr 23. No abstract available.

PMID:
31012358
23.

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.

Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP.

Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.

PMID:
30963592
24.

Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles.

Lyapichev KA, Sukswai N, Konoplev S, Khoury JD.

Ann Hematol. 2019 Sep;98(9):2221-2222. doi: 10.1007/s00277-019-03675-1. Epub 2019 Apr 7. No abstract available.

PMID:
30955062
25.

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.

Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2432-2440. doi: 10.1080/10428194.2019.1597081. Epub 2019 Apr 3.

PMID:
30942648
26.

Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease.

Sukswai N, Lyapichev K, Medeiros LJ, Khoury JD.

Clin Case Rep. 2019 Feb 7;7(3):587-588. doi: 10.1002/ccr3.2015. eCollection 2019 Mar.

27.

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):447-455. doi: 10.1016/j.ijrobp.2019.02.002. Epub 2019 Feb 12.

PMID:
30769175
28.

Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.

Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):244-250. doi: 10.1016/j.clml.2018.12.016. Epub 2019 Jan 3.

PMID:
30686775
29.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN.

Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.

30.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21.

PMID:
30575820
31.

Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.

Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA.

Onco Targets Ther. 2018 Dec 10;11:8937-8942. doi: 10.2147/OTT.S159843. eCollection 2018.

32.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.

Cancer. 2019 Feb 15;125(4):559-574. doi: 10.1002/cncr.31831. Epub 2018 Dec 3.

PMID:
30508305
33.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
34.

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.

Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S.

Oncotarget. 2018 Nov 2;9(86):35611-35622. doi: 10.18632/oncotarget.26242. eCollection 2018 Nov 2.

35.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation.

Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N.

J Clin Pathol. 2019 Mar;72(3):251-257. doi: 10.1136/jclinpath-2018-205399. Epub 2018 Nov 22.

PMID:
30467242
36.

Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine-needle aspiration biopsy.

Foshat M, Stewart J, Khoury JD, Staerkel GA, Caraway NP.

Cancer Cytopathol. 2019 Feb;127(1):44-51. doi: 10.1002/cncy.22077. Epub 2018 Nov 19.

PMID:
30452126
37.

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD.

Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.

38.

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.

Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e51-e61. doi: 10.1016/j.clml.2018.09.002. Epub 2018 Sep 10.

PMID:
30360985
39.

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Khoury JD.

Curr Hematol Malig Rep. 2018 Dec;13(6):477-483. doi: 10.1007/s11899-018-0489-z. Review.

PMID:
30350260
40.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

41.

Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

Sanz-De Pedro M, Wang W, Kanagal-Shamanna R, Khoury JD.

Curr Hematol Malig Rep. 2018 Dec;13(6):467-476. doi: 10.1007/s11899-018-0483-5. Review.

PMID:
30338456
42.

Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation.

Garces S, Yin CC, Patel KP, Khoury JD, Manning JT Jr, Li S, Xu J, Pina-Oviedo S, Johnson MR, González S, Molgó M, Ruiz-Cordero R, Medeiros LJ.

Mod Pathol. 2019 Jan;32(1):16-26. doi: 10.1038/s41379-018-0152-1. Epub 2018 Oct 15.

PMID:
30323237
43.

Recent Updates on Chronic Myelomonocytic Leukemia.

Loghavi S, Khoury JD.

Curr Hematol Malig Rep. 2018 Dec;13(6):446-454. doi: 10.1007/s11899-018-0475-5. Review.

PMID:
30311069
44.

Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.

Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, Khoury JD, Xu B, Huang S, Qiu Y.

Leukemia. 2019 Apr;33(4):931-944. doi: 10.1038/s41375-018-0279-6. Epub 2018 Oct 5.

PMID:
30291336
45.

Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events.

Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP, Hu S, Lu X, Toruner GA, Medeiros LJ, Khoury JD.

Leuk Res. 2018 Oct;73:86-94. doi: 10.1016/j.leukres.2018.09.006. Epub 2018 Sep 17.

PMID:
30248580
46.

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival.

Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD.

Am J Hematol. 2018 Nov;93(11):1376-1383. doi: 10.1002/ajh.25255. Epub 2018 Sep 23.

47.

Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.

Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S.

Hum Pathol. 2018 Dec;82:215-231. doi: 10.1016/j.humpath.2018.07.030. Epub 2018 Aug 4.

PMID:
30086334
48.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.

Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD.

Blood Adv. 2018 Aug 14;2(15):1807-1816. doi: 10.1182/bloodadvances.2018019224.

49.

Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.

Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna R.

Mod Pathol. 2018 Nov;31(11):1717-1732. doi: 10.1038/s41379-018-0093-8. Epub 2018 Jun 28.

50.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571

Supplemental Content

Loading ...
Support Center